Smith & Nephew (LON:SN) Given New GBX 1,250 Price Target at Royal Bank Of Canada

Smith & Nephew (LON:SN) had its price objective lowered by stock analysts at Royal Bank Of Canada from GBX 1,350 to GBX 1,250 in a report issued on Thursday,London Stock Exchange reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 11.41% from the stock’s previous close.

SN has been the topic of a number of other reports. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a research report on Friday, May 1st. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. UBS Group reissued a “neutral” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a report on Tuesday, May 5th. JPMorgan Chase & Co. cut their target price on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,400 price target on shares of Smith & Nephew in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Smith & Nephew has an average rating of “Hold” and an average target price of GBX 1,172.56.

Smith & Nephew Price Performance

LON:SN opened at GBX 1,122 on Thursday. The firm has a fifty day moving average price of GBX 1,135.98 and a 200-day moving average price of GBX 1,194.09. The company has a current ratio of 2.14, a quick ratio of 0.84 and a debt-to-equity ratio of 73.07. The stock has a market cap of £12.30 billion, a PE ratio of 40.40, a P/E/G ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.